過活動膀胱治療市場：薬物療法、疾患タイプ、流通別-2025-2030年の世界予測

過活動膀胱治療市場は、2023年に45億4,000万米ドルと評価され、2024年には47億1,000万米ドルに達すると予測され、CAGR 3.74％で成長し、2030年には58億8,000万米ドルに達すると予測されています。

過活動膀胱（OAB）治療市場は、尿意切迫感、頻尿、失禁などの症状を管理するために設計された製品および治療ソリューションに焦点を当て、世界中の個人を対象としています。効果的な過活動膀胱治療の必要性は、人口の高齢化と膀胱障害の有病率の増加から生じており、患者の生活の質を向上させるために薬理学的および非薬理学的治療の継続的な技術革新が必要とされています。アプリケーションは、経口薬や膀胱内療法から先進的な神経調節装置や行動介入まで多岐にわたり、エンドユーザーは病院、泌尿器科クリニック、在宅医療環境などに及んでいます。市場成長は、薬剤製剤の進歩、ヘルスケア支出の増加、認知度や診断率の向上といった要因に影響されます。医薬品や医療機器の技術的進歩は、特に標的生物製剤や低侵襲治療の開発において貴重な機会を提供する一方、製薬企業と研究機関の協力関係の増加は、革新的な解決策の育成に役立ちます。課題としては、新たな治療法に伴う高コスト、規制上のハードル、発展途上地域における認知度の低さなどがあり、成長の可能性を制約する可能性があります。既存の治療法の安全性への懸念や副作用は、患者のコンプライアンスや採用をさらに複雑にしています。戦略的提言としては、既存の治療法の有効性を高め、副作用を軽減するための研究開発への投資が挙げられます。企業は、治療計画を最適化するために、患者中心のイノベーションとデジタル化に注力することが推奨されます。例えば、患者モニタリングと個別化された治療調整のためにAIと機械学習を導入することが挙げられます。イノベーションはまた、全人的な管理のために生活習慣への介入を薬物療法と統合する併用アプローチに焦点を当てることもできます。需要の拡大に伴い、戦略的パートナーシップや効率的なサプライチェーンの枠組みを通じて、新興市場での拡大余地は大きいです。OAB治療市場は依然としてダイナミックであり、成長を維持し患者ケアを強化するために不可欠な、革新的で費用対効果が高く、利用しやすいソリューションに向けた力強い軌跡を描いています。

市場力学：急速に進化する過活動膀胱治療市場の主要市場インサイトを公開

過活動膀胱治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 過活動膀胱（OAB）症状のある人の増加
  • 高齢化人口の増加
• 市場抑制要因
  • 過活動膀胱治療に関連する副作用とリスク
• 市場機会
  • 過活動膀胱の臨床研究試験とパイプライン
• 市場の課題
  • 過活動膀胱の認知度の低さ

ポーターの5つの力：過活動膀胱治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：過活動膀胱治療市場における外部からの影響の把握

外部マクロ環境要因は、過活動膀胱治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析過活動膀胱治療市場における競合情勢の把握

過活動膀胱治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス過活動膀胱治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、過活動膀胱治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨過活動膀胱治療市場における成功への道筋を描く

過活動膀胱治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 過活動膀胱（OAB）症状を持つ人の数の増加
    • 高齢化人口の増加
  • 抑制要因
    • 過活動膀胱治療に関連する副作用とリスク
  • 機会
    • 過活動膀胱の臨床調査試験とパイプライン
  • 課題
    • OAB状態に関する認識の限界
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 過活動膀胱治療市場薬物療法別

• 抗コリン剤
• ボト
• ダリフェナシン
• フェソテロジン
• ミラベグロン
• 神経刺激
• オキシブチニン
• ソリフェナシン

第7章 過活動膀胱治療市場：疾患タイプ別

• 特発性膀胱過活動症
• 神経因性膀胱過活動

第8章 過活動膀胱治療市場配布元

• 病院および院内薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの過活動膀胱治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の過活動膀胱治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの過活動膀胱治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Allergan plc
• Astellas Pharma Inc.
• Cipla Limited
• DETROL LA by Viatris Company
• Endo International plc
• Granules India Limited
• Hisamitsu Pharmaceutical Co., Inc.
• Medtronic plc
• Mylan N.V.
• Pfizer Inc.
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Urovant Sciences Inc.
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. OVERACTIVE BLADDER TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL & HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 34. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 51. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 118. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 150. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Overactive Bladder Treatment Market was valued at USD 4.54 billion in 2023, expected to reach USD 4.71 billion in 2024, and is projected to grow at a CAGR of 3.74%, to USD 5.88 billion by 2030.

The overactive bladder (OAB) treatment market focuses on products and therapeutic solutions designed to manage symptoms such as urinary urgency, frequency, and incontinence affecting individuals worldwide. The necessity for effective OAB treatments arises from a growing aging population and increased prevalence of bladder disorders, which necessitates ongoing innovation in pharmacological and non-pharmacological therapies to improve patient quality of life. Applications extend from oral medications and intravesical therapies to advanced neuromodulation devices and behavioral interventions, with end-users encompassing hospitals, urological clinics, and home healthcare settings. Market growth is influenced by factors such as advancements in drug formulations, increasing healthcare expenditure, and heightened awareness and diagnosis rates. Technological advancements in pharmaceuticals and medical devices present valuable opportunities, particularly in the development of targeted biologics and minimally invasive treatments, while increasing collaborations between pharmaceutical companies and research institutions can aid in fostering innovative solutions. Challenges include high costs associated with new treatment modalities, regulatory hurdles, and limited awareness in developing regions, which may constrain growth potential. Safety concerns and side effects of existing treatment options further complicate patient compliance and adoption. Strategic recommendations involve investing in R&D to enhance the efficacy and reduce side effects of existing treatments. Companies are encouraged to focus on patient-centric innovations and digitization to optimize treatment plans; for instance, deploying AI and machine learning for patient monitoring and personalized therapy adjustments. Innovation could also focus on combinatory approaches that integrate lifestyle interventions with pharmacotherapy for holistic management. With growing demand, there is significant room for expansion in emerging markets through strategic partnerships and efficient supply chain frameworks. The OAB treatment market remains dynamic, with a strong trajectory toward innovative, cost-effective, and accessible solutions crucial for sustaining growth and enhancing patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Overactive Bladder Treatment Market

The Overactive Bladder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in number of people with overactive bladder (OAB) symptoms
  • Increase in aging population
• Market Restraints
  • Adverse effects and risk associated with overactive bladder treatment
• Market Opportunities
  • Overactive bladder clinical research trials and pipeline
• Market Challenges
  • Limited awareness of OAB condition

Porter's Five Forces: A Strategic Tool for Navigating the Overactive Bladder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Overactive Bladder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Overactive Bladder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Overactive Bladder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Overactive Bladder Treatment Market

A detailed market share analysis in the Overactive Bladder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Overactive Bladder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Overactive Bladder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Overactive Bladder Treatment Market

A strategic analysis of the Overactive Bladder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Overactive Bladder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Astellas Pharma Inc., Cipla Limited, DETROL LA by Viatris Company, Endo International plc, Granules India Limited, Hisamitsu Pharmaceutical Co., Inc., Medtronic plc, Mylan N.V., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Urovant Sciences Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Overactive Bladder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Therapy, market is studied across Anticholinergic, BOTO, Darifenacin, Fesoterodine, Mirabegron, Neurostimulation, Oxybutynin, and Solifenacin.
• Based on Disease Type, market is studied across Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.
• Based on Distribution, market is studied across Hospital & Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in number of people with overactive bladder (OAB) symptoms
    • 5.1.1.2. Increase in aging population
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse effects and risk associated with overactive bladder treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Overactive bladder clinical research trials and pipeline
  • 5.1.4. Challenges
    • 5.1.4.1. Limited awareness of OAB condition
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Overactive Bladder Treatment Market, by Drug Therapy

• 6.1. Introduction
• 6.2. Anticholinergic
• 6.3. BOTO
• 6.4. Darifenacin
• 6.5. Fesoterodine
• 6.6. Mirabegron
• 6.7. Neurostimulation
• 6.8. Oxybutynin
• 6.9. Solifenacin

7. Overactive Bladder Treatment Market, by Disease Type

• 7.1. Introduction
• 7.2. Idiopathic Bladder Overactivity
• 7.3. Neurogenic Bladder Overactivity

8. Overactive Bladder Treatment Market, by Distribution

• 8.1. Introduction
• 8.2. Hospital & Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Overactive Bladder Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Overactive Bladder Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Overactive Bladder Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Astellas Pharma Inc.
• 4. Cipla Limited
• 5. DETROL LA by Viatris Company
• 6. Endo International plc
• 7. Granules India Limited
• 8. Hisamitsu Pharmaceutical Co., Inc.
• 9. Medtronic plc
• 10. Mylan N.V.
• 11. Pfizer Inc.
• 12. Sunovion Pharmaceuticals Inc.
• 13. Teva Pharmaceutical Industries Ltd.
• 14. Urovant Sciences Inc.
• 15. Zydus Lifesciences Limited